2. Early dapagliflozin (Farxiga)
treatment before hospital
discharge for acute heart failure
is safe and beneficial. It helps
remove excess fluids, reduces the
need for strong diuretics, and
speeds up recommended
treatment initiation, as shown in
a study with 238 patients in
Amsterdam.
the study's findings encourage
doctors to start SGLT2
inhibitor treatment early
during hospitalization and
continue it afterward.
The essential message is to start
the recommended therapy
before the patient is
discharged from the
hospital.
Ref-https://www.medscape.com/viewarticle/996170
3. •Dr. Wiviott explained that the primary
endpoint's lack of significance in the study
was because it was small.
•A bigger study called DAPA ACT HF-TIMI
68 is ongoing to give more certain results
about dapagliflozin's safety and
effectiveness in acute heart failure.
•This larger study includes about 2400
patients and is measuring the combined
rate of cardiovascular death or worsening
heart failure for 2 months after
randomization.
•We expect to see the results in 2024.
SOLOIST-WHF trial tested a drug called
sotagliflozin in heart failure patients. Only
142 out of 596 participants started taking
it before leaving the hospital.
In the EMPULSE trial, 530 people with
acute heart failure were randomly given
either empagliflozin or a placebo during
their hospital stay. They measured the
results using a questionnaire about
symptoms.
The DICTATE-AHF study involved 238
adults with hypervolemic acute heart
failure. They all got standard IV diuretics
treatment, and half also received a daily
dose of dapagliflozin.
Dr. Stephen Wiviott, a Harvard Medical
School professor and cardiologist, pointed
out that guidelines recommend starting
SGLT2 inhibitors during acute heart failure
hospitalization, but there hasn't been much
proof of their safety and effectiveness.
Ref-https://www.medscape.com/viewarticle/996170
5. Even an Hour's Walk
a Week Lowers Risk
in Type 2 Diabetes
Walking just one hour per week
reduces the risk of Type 2 diabetes.
6. T 4
A study of 18,000+ people in the UK Biobank shows that even a little exercise, like a short walk under 1.5
hours per week, can lower the risk of nerve and kidney problems in type 2 diabetes by 20% to 33%. This is
good news for doctors and patients.
This study is good news for
nerve problems in diabetes
because there's no cure and
few prevention methods. Most
diabetes research focuses on
big health issues, but we found
that even a small amount of
exercise can help a lot,
especially with nerve problems.
We know exercise is important for managing type 2 diabetes, but its
effects on small complications were unclear due to mixed evidence.
So, researchers studied people aged 37-82 with type 2 diabetes to see
how different exercise levels impact nerve, kidney, and eye issues.
7. Over 12 years, 3.7% had
nerve problems, 10.2%
had kidney problems,
and 11.7% had eye
problems. That's roughly
3.5, 9.8, and 11.4 out of
every 1,000 people each
year.
How They Checked Activity:
The researchers asked people about
what they do for fun, how often, and
for how long.
Recommended Exercise:
Health advice says it's good to do
activities that make you a bit sweaty
and out of breath for about 150
minutes (or 2.5 hours) every week.
1.Study Population:
•18,092 people in
the study.
•37% were women.
•Average age was
60.
2.Exercise Levels:
•10% didn't do any
leisure-time
exercise.
•38% did less
exercise than
recommended.
•20% met
recommended
exercise levels.
•32% were more
active.
8. “Testing for albumin in the urine is important but not
used enough. It helps find kidney problems early."
Albuminuria Testing
Underutilized, Crucial in CKD
Detection
9. Study Participants:
192,000+ patients were studied from 2007 to 2018.
Most had hypertension (96.6%) and some had diabetes (26.2%).
Albuminuria Testing:
Only 17.5% of the patients (around 33,629 people) were tested for
albuminuria.
Results of Testing:
Among those tested, 34.3% showed signs of albuminuria.
Estimation for Untested Patients:
An estimated 13.4% of the 158,479 patients who were not tested had
albuminuria.
Detection Rate:
Only 35.2% of the people with albuminuria were actually tested for it.
.
The study suggests that many people with albuminuria, a potential sign of CKD, have not been
tested for it.
Detecting albuminuria early is crucial because there are treatments like SGLT2 inhibitors that can slow
down CKD and prevent heart problems.
Ref-https://www.medscape.com/viewarticle/995740
10. Tested people got more important medications.
They also got SGLT2 inhibitors and had better blood
pressure.
Not testing for albuminuria is a big problem because
it makes it harder to find and treat chronic kidney
disease (CKD) and prevent heart issues.
Guidelines don't stress albuminuria testing enough.
Many people are not aware of the importance of this
simple test.
These are the main reasons why albuminuria testing
is not done enough.
Lack of clear guidelines on who should be tested
and how often, as well as a need for a urine sample,
are major reasons for inadequate albuminuria
testing.
Many guidelines focus only on eGFR and forget
about albuminuria, making it less likely to be tested.
Ref--https://www.medscape.com/viewarticle/995740
11. CLINICAL TRIAL
SHOWS DRUG
DEVELOPED TO TREAT
UNCONTROLLED
HYPERTENSION
SIGNIFICANTLY
LOWERS BLOOD
PRESSURE !
A special Anti-hypertensive
medicine was found and tested
and it really helps people with
high blood pressure by bringing
it down a lot."
Ref-https://southfloridahospitalnews.com
12. Lorundrostat studied in 200 patients
New Blood
Pressure Medicine
Lorundrostat is a
new medicine
that helps lower
high blood
pressure.
01 02
Study and
Presentation
A study about
Lorundrostat was shared
at a Heart Association
meeting and published in
a medical journal.
05
Importance of
the Findings:
New blood pressure
medicines are rare
and can be very
useful, especially for
those with obesity
and diabetes.
04
Study Details
200 patients were part of the
study, trying different
doses of Lorundrostat or
(placebo). Higher doses
helped more.
Patients who were
overweight got good
results.
03
How
Lorundrostat
Works
Lorundrostat
targets a
hormone called
aldosterone,
which affects
blood pressure.
Ref-https://southfloridahospitalnews.com
